ClinicalTrials.Veeva

Menu

Study of Oxycyte in Severe Closed Head Injury

T

Tenax Therapeutics

Status and phase

Completed
Phase 2

Conditions

Traumatic Brain Injury

Treatments

Drug: perfluorocarbon emulsion (Oxycyte) infusion

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00174980
OX-CL-II-002

Details and patient eligibility

About

Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in better brain oxygen consumption, less cell death, and better functional outcome. This study will test the hypothesis that Oxycyte is an effective way to increase brain oxygen levels in severe head injury.

Full description

Decreased brain oxygen in severe brain injuries appears to be implicated in poor functional outcome and death. Animal and clinical studies have shown that increasing brain oxygen in such patients improves functional outcome, and Oxycyte has been shown to be an effective means of delivering oxygen to tissues, including the brain. This study is an eight patient proof of concept study to test the effects of oxygen delivery with Oxycyte in patients with a severe traumatic head injury with a Glasgow Coma Scale (GCS) score of 3 to 9.

Subjects diagnosed with a severe head injury (GCS 3-9) who receive a brain oxygen monitor and microdialysis catheter, will undergo baseline monitoring for 4 hours. In the first 4 subjects the Fi02 on the ventilator will be increased to 50% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 50% for 24 hours.

In the second 4 subjects the Fi02 on the ventilator will be increased to 100% for a 4 hour stabilization period and this will be followed by a single intravenous infusion of 3ml/kg of Oxycyte. The Fi02 will remain at 100% for 24 hours.

Subjects will be enrolled, treated, and then monitored by LICOX 02 monitor before and after infusion of PFC, and then for at least 48 hours following the discontinuation of Oxycyte.

Enrollment

9 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • severe closed head injury patients or GCS 3-9 patients who receive brain oxygen monitoring
  • ventriculostomy/ICP monitor
  • at least one reactive pupil
  • no known life threatening disease prior to trauma
  • age 18-70 years old
  • consent for microdialysis/brain 02 monitoring
  • legal family representative present that can give informed consent for perfluorocarbon administration

Exclusion criteria

  • no motor response
  • both pupils fixed and dilated
  • no consent available
  • allergy to egg proteins
  • coagulopathy
  • major liver injury
  • major pulmonary injury

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems